SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Anlon Healthcare to acquire 57% stake in Bizotic Lifescience

29 Nov 2025 Evaluate

Anlon Healthcare has entered into a Share Purchase Agreement (SPA) with Bizotic Lifescience (Target Company), on November 28, 2025, for acquisition of 56.67% shareholding of the Target Company from multiple existing shareholders of such Target Company. The company will acquire 25.50 lakh equity shares of the Target Company at a price of Rs 14.89 each, taking the deal value to around Rs 3.80 crore.  Pursuant to the terms of the SPA and upon fulfilment of conditions precedent contained in the SPA, the company will acquire management and control of the Target Company, and upon completion of such acquisition, the Target Company will become subsidiary of the company.

The proposed acquisition of the Target Company will enable the company to augment its existing manufacturing capacity through access to ready-to-operate facilities. The acquisition also provides immediate availability of validated production lines and established process systems, which helps avoid the longer timelines typically associated with land acquisition, construction, regulatory approvals, equipment installation, and plant validation for a greenfield project. As a brownfield investment, the transaction is expected to provide faster operational readiness, reduce regulatory and execution-related uncertainties, and support earlier revenue contribution. The transaction is expected to strengthen the company’s operational efficiency and long-term competitiveness.

Anlon Healthcare is a chemical manufacturing company engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in India and international markets.

Anlon Healthcare Share Price

15.08 0.10 (0.67%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: